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Schlüsselwörter
Biomarker · Mammakarzinom, luminales · 
 Genexpression · Prognostische Marker 
Zusammenfassung
Fortschritte bei Genexpressionsanalysen erlauben eine 
Einteilung des Hormonrezeptor-positiven (luminalen) 
Mammakarzinoms in verschiedene prognostische Unter-
gruppen. Diese Subklassifikation wird in der klinischen 
Routine als prognostische Gensignatur (z.B. 21 Gene/On-
cotype DX®, 70 Gene/Mammaprint®) genutzt. Die opti-
male Methode zur Sub-Klassifizierung ist jedoch noch 
nicht definiert. Bisher fehlt die Evidenz prospektiver Stu-
dien. Diese Übersichtsarbeit analysiert die am weitesten 
verbreiteten genomischen Signaturen im Sinne einer kri-
tischen Bestandsaufnahme der aus retrospektiven/pros-
pektiven Studien verfügbaren Evidenz. Diese Analyse 
basiert auf einer systematischen Literaturrecherche mit-
tels Medline, sowie der bis September 2013 veröffent-
lichten Abstracts beim Annual Meeting of American So-
ciety of Clinical Oncology und San Antonio Breast 
Cancer Symposium.
Keywords
Biomarker · Breast cancer · Gene expression · 
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Summary
The developments in gene expression analysis have 
made it possible to sub-classify hormone receptor-posi-
tive (luminal) breast cancer in different prognostic 
 subgroups. This sub-classification is currently used in 
clinical routine as prognostic signature (e.g. 21-gene 
 Onoctype DX®, 70-gene Mammaprint®). As yet, the opti-
mal method for sub-classification has not been defined. 
Moreover, there is no evidence from prospective trials. 
This review explores widely used genomic signatures in 
luminal breast cancer, making a critical appraisal of evi-
dence from retrospective/prospective trials. It is based 
on systematic literature search performed using Medline 
(accessed September 2013) and abstracts presented at 
the Annual Meeting of American Society of Clinical On-
cology and San Antonio Breast Cancer Symposium.
Introduction
Even with the significant progress in early detection and 
treatment of hormone receptor (HR)-positive (estrogen re-
ceptor (ER)- and/or progesterone receptor (PR)-positive) 
breast cancer (BC), it remains the most common female can-
cer in Western Europe, with at least 3 million newly diag-
nosed cases in 2010, and is still a potentially deadly disease. 
Currently, the major clinical challenges in HR+ luminal BC 
are: (1) frequent overtreatment by adjuvant chemotherapy 
(CT) in about 70% of cases, based on classical clinical-patho-
logical criteria (tumor size, nodal status, age); (2) selection of 
patients for extended endocrine therapy (ET) – it was re-
cently shown that ET for 10 years is superior to that for 
5 years [1]; and (3) finding predictive factors for targeted 
 therapies that aim to overcome endocrine resistance [2].
The progress in high-throughput analysis of gene expres-
sion has led to a substantial change in our understanding of 
BC. Although HR status was already known as a predictive 
factor for ET efficacy and as a prognostic factor for BC, the 
work of Perou et al. [3], and Sorlie et al. [4] demonstrated that 
BC is a heterogeneous disease with distinct subtypes, but 
(sometimes) similar histomorphological characteristics. For 
the cDNA analysis (n = 8,102 genes), Perou and Sorlie used a 
small number (n = 40, and n = 78 in the second analysis) of 
fresh frozen BC samples. Hierarchical clustering analysis 
 revealed 5 molecular subtypes that were relatively stable 
and intrinsic (mostly driven by genes of the same tumor). 
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In addition, they were able to correlate these 5 molecular sub-
types with differential patient outcome.
This work pointed to ER as a major factor in disease devel-
opment and its subsequent biological and clinical characteris-
tics. Most ER+ cases can be assigned to the luminal A or B 
subgroup (named after the similarity of their gene expression 
with that of luminal cells of the normal breast gland). Prolifer-
ation-related genes seem to play a major role in the differen-
tiation between both luminal subtypes. Low-proliferating 
 luminal A tumors are associated with better prognosis and 
lower chemosensitivity than the high-proliferative, frequently 
poor grade luminal B subtype [4].
The molecular classification according to the definition of 
Perou et al. is often criticized because of the retrospective na-
ture of the analysis, the small number of tumor samples used 
for the first analysis (n = 78), and the limited number of histo-
logical subtypes within small studies. Moreover, although the 
use of hierarchical clustering as a statistical method is widely 
applied in hypothesis-generating studies, it is not practicable 
for clinical use or prospective allocation of patients to the 
 subtypes [5]. 
Molecular Subtypes
Allocation of tumors to either luminal subtype seems to be 
rather less dependable than that for basal-like and HER2 
 subtypes. Thus, if a nearest centroid predictor is used for 
 allocation, many cases remain unclassified due to the low cor-
relation with the subtype centroid [6]. Weigelt et al. [7] pub-
lished a substantial lack of reproducibility of luminal subtypes 
using a single sample predictor method (similarity between 
subtype centroid and given case). There is only a moderate to 
weak correlation regarding luminal A or B subtypes between 
different datasets despite of a similar prognostic impact, thus 
underlining the mere research character of the molecular 
classification.
For clinical use, the PAM50 signature (as part of the Pros-
igna® test, NanoString Inc., Seattle, WA, USA) was devel-
oped as an mRNA quantitative reverse transcription PCR 
based on a 50-gene (and 5 reference genes) assay for sub-clas-
sification into the 4 molecular subtypes (luminal A/B, basal-
like, and HER2). PAM50 is incorporated into a continuous 
Risk of Relapse (ROR) score [8], which includes the weight-
ing of proliferation genes within molecular subtypes with/
without tumor size (ROR-S/-C). It allocates patients into 1 of 
3 risk categories (low (< 10% distant relapses)/intermediate/
high risk (> 20%) in N0 BC. This signature significantly in-
creases the prognostic impact of the intrinsic subtypes alone 
[8], and has been shown to be prognostic while showing that 
the outcome of the luminal B subtype may be quite compara-
ble to basal-like and HER2 subtypes. The prognostic impact 
of ROR/PAM50 was confirmed in several retrospective anal-
yses of prospective studies. In patients treated by tamoxifen Ta
b
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alone, the intrinsic subtype and ROR score were significant 
prognostic factors together with tumor stage [9]. Moreover, 
the luminal subtype determined by PAM50 was more predic-
tive for tamoxifen benefit compared to ER status determined 
by immunohistochemistry (IHC) in premenopausal patients 
treated within the NCIC MA-12 study [10]. Later, Ellis et al. 
[11] showed similar activity for neoadjuvant ET in both lumi-
nal A/B subtypes. There is some published work on the pre-
dictive impact of PAM50 for anthracycline (in the HER2 sub-
group) [12] and paclitaxel benefit – surprisingly in the low 
proliferation group [13] – next to a significant prognostic im-
pact in these smaller retrospective analysis. However, despite 
strong evidence for a predictive impact of pathological com-
plete response (pCR) within the neoadjuvant CT (NACT) 
setting, with a 2.3–5.3-fold increase in the pCR rate in the 
 luminal B compared to the luminal A subtype [14], there is 
still no predictive data for the efficacy of CT + ET versus ET 
alone. The significant prognostic impact of ROR has recently 
been retrospectively validated within the TransATAC and 
ABCSG-08 postmenopausal collectives treated by ET alone. 
In both studies, ROR provided additional prognostic informa-
tion beyond clinical variables for both early and late metasta-
sis. Both luminal A and B subtypes and ROR score have 
shown a prognostic impact over both time periods (0–5 and 
5–10 years) and provided information in addition to the clini-
cal factors [15, 16]. A recently presented meta-analysis of the 
trials in N+ patients confirmed that a large proportion of 
N+ patients had a low risk (particularly patients with 1–2 posi-
tive lymph nodes) [17]. However, the lack of predictive data 
for the efficacy of adjuvant CT and extended ET, and of deci-
sion impact or health economic evaluation studies, are a 
major consideration for not recommending the PAM50 assay 
for routine clinical use at the moment. Currently, there are 
already 2 prospective observational studies of clinical out-
comes for the NanoString® Technologies’ Breast Cancer 
 Intrinsic Subtype Test (BCIST), 1 in Spain run by GEICAM 
and 1 in Germany run by WSG (Women’s Healthcare Study 
Group, www.wsg-online.com). Similar studies are planned 
with separate but also common analyses to look at the health 
economic impact in different reimbursement systems.
Whole Genome Sequencing
Besides the controversial discussion regarding standardiza-
tion of the molecular classification, over the last few years 
the results of whole genome sequencing of tumors have been 
published [18]. The luminal subtype (in contrast to basal- 
like  tumors) was shown to be characterized by an activated 
ER-FOXA1 complex. The luminal A subtype (defined by 
mRNA) harbored significantly more PIK3CA mutations than 
the luminal B subtype (45% vs. 29%), followed by more 
MAP3K1, and GATA3 and fewer TP53 mutations (12% vs. 
29%). However, markers of PIK3CA activation were not 
 elevated in luminal tumors (compared to basal tumors) [19]. 
GATA3 was also reported to be associated with the aro-
matase inhibitor (AI) response, and the MAP kinase gene 
MAP3K1 with both low proliferation levels pre- and post-AI 
treatment [11]. In the same paper, a significant difference in 
the number of point mutations was seen between AI-sensitive 
and -resistant cases. 
In addition to PAM50, which aims to standardize the mo-
lecular classification of BC, several prognostic gene signatures 
have been developed for exact prognosis estimation, particu-
larly in HR+ BC (detailed in table 1). Most of the genes in-
cluded are involved in proliferation [20], so that to understand 
their additional prognostic and/or predictive impact compared 
to classical clinical-pathological or IHC characteristics alone, 
a comparison with a central and independent pathology as-
sessment of these factors is required. 
IHC-Based Classification
Based on the assumption that proliferation is vital for the 
differentiation between luminal A and B subtypes, several 
 attempts have been undertaken to replace gene signatures by 
surrogate IHC markers (e.g. ER, PR, Ki-67, HER2) and/or 
histological grade assessment [21]. Cheang et al. [87] pub-
lished a Ki-67 cut-off of ~14% as an optimal discriminator be-
tween  luminal A and B subtypes (sensitivity 72%; specificity 
78%). Therefore, high Ki-67 and/or positive HER2 status 
were proposed for the definition of luminal B tumors. The 
 biological rationale behind this definition and a correlation 
with the intrinsic subtype led to the inclusion of the 14% 
Ki-67 cut-off into the St. Gallen guidelines in 2011, and to the 
proposed relative indication for a sequential chemoendocrine 
therapy in ‘luminal B’ tumors. However, there is still no con-
sensus about the optimal measurement method and optimal 
cut-off of Ki-67 [22]. A significant inter-observer variability 
was confirmed in an international multicenter study (about 
1/3 of  patients were discordantly allocated to the luminal A 
vs. B subtypes) [23]. There are several retrospective analyses 
from prospective trials that confirm a strong prognostic im-
pact of an IHC-based definition of the luminal A and B sub-
types [24]. However, 2 recent studies have shown that Ki-67 
as a continuous variable (as proposed by the International 
Consensus) and/or centrally measured grade (as a surrogate 
for molecular subtype) can provide comparable prognostic in-
formation to that derived from any genomic signature [25, 26]. 
Although several papers confirm a predictive impact of 
high Ki-67 with respect to an increase of pCR in the NACT 
setting [24], to a benefit from taxanes in addition to anthracy-
clines in the adjuvant setting [25, 27, 28] as well as to a benefit 
of NACT versus ET in the ‘luminal B’ subtype [29], so far no 
predictive effect of Ki-67 for benefit of adjuvant CT+ET ver-
sus ET alone has been shown [30]. This is difficult to under-
stand in view of the prognostic impact of pCR particularly in 
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the population in the SWOG trial (38% vs. 21%) [42, 43]. The 
10-year overall survival (OS) rates were equal in both studies 
(L vs. H risk: 77%/74% vs. 51%/54%). Nevertheless, the most 
important finding from this analysis was the predictive effect 
of RS for the benefit of CT-ET compared to ET alone in the 
RS H-risk group (hazard ratio = 0.59, p = 0.033), but not in 
the RS L-risk group (hazard ratio = 1.02, p = 0.97). None of 
the conventional prognostic factors were predictive for CT 
benefit by interaction analysis if RS was included. Curves for 
the benefit from CT (in the N1 and N2 subgroup) started to 
split at an RS of 20 (for the 0–5-year endpoint). In this study 
and in subsequent analyses, the prognostic and predictive 
 impact of RS was stronger in the first 5 years of follow up than 
in years 5–10. There is further retrospective evidence from 
prospective trials, such as the E2197 [44] and NSABP B-28 
studies, confirming a strong significant prognostic impact in 
addition to conventional markers, although no predictive 
 impact with respect to paclitaxel CT was shown in the later 
trial [45]. 
Furthermore, several studies have indicated a prognostic 
impact of 21-gene RS, as shown by a good correlation be-
tween RS and loco-regional relapse (LRR). There was a very 
low LRR rate in the L- compared to the H-risk group, with: 
1–4% versus 10–18%, respectively [46, 47]. A strong prognos-
tic impact in primary metastatic ER+ BC – as the last step of 
BC development – has recently been presented, showing a 
2-year OS of 100% in the L-risk HR+/HER2 group compared 
with 69% in the H-risk group (n = 70) [48].
Combination of Oncotype DX with further clinical factors 
(tumor size, age, grade), i.e. RS-pathological-clinical (RSPC), 
can increase the prognostic value of the test and reduce num-
ber of patients classified as L risk (with/without RSPC: 17.8% 
vs, 26.7%). However, it was less predictive by interaction 
analysis with regards to a CT benefit in the NSABP B-20 trial 
[40].
There are several decision impact studies from different 
countries evaluating the impact of RS in clinical routine. 
A change in CT decisions was reported in about 1/3 of pa-
tients in the pooled analysis, confirming L risk in 49% of cases 
(n = 1,437) [49]. RS has been evaluated in several randomized 
trials with first prospective evidence expected from the Tai-
lorX trial in 2015. This trial (2007–2011) aimed to confirm a 
94% 5-year DFS in the L-risk group and investigate the CT 
impact in the IM risk group (RS 12–25) in N0 disease. The 
ongoing RxPonder trial is addressing the question of CT + ET 
versus ET alone in N1 L and IM risk by RS (RS 0–25) patients 
with N1 BC (n = 4,000). The WSG ADAPT trial is investigat-
ing the CT decision in the N0–1 IM risk by RS depending on 
early ET response (n = ~1,600 by ET alone). This is a follow-
up trial to the planB trial (2009–2011) in which 318 patients 
with clinical IM or H risk and low RS opted for omission of 
CT. 
The NCCN [50], ASCO [51], and current St. Gallen Con-
sensus Panel [32] have recommended that the use of RS be 
the luminal B-like but not in the luminal A disease [31]. Be-
cause of these methodological difficulties, the most recent 
St. Gallen Consensus Panel in 2013 voted for changing the 
Ki-67 cut-off to 20% (used by most groups for analysis) as an 
‘IHC-surrogate’ definition of the luminal B subtype [32]. 
IHC scores such as IHC4, which uses centrally determined 
ER, PR, HER2, Ki-67, or Mammostrat [33], are highly effec-
tive methods for classifying HR+ BC into prognostic sub-
groups. Dowsett et al. [34] published a similar prognostic im-
pact of the IHC4 score compared to Oncotype DX® (Genomic 
Health Inc., Redwood City, CA, USA), and the ROR score. 
However, this could not be confirmed by other groups for the 
comparison of ROR versus IHC4 or IHC-based subtype [35]. 
Interestingly, Prat et al. [35] proposed the inclusion of 
PR > 20% into the luminal A definition. Other data from the 
WSG EC-Doc trial also reported a highly significant impact of 
PR expression within the luminal B subtype for the definition 
of 2 groups with distinct outcome (i.e. luminal B tumors with 
high PR expression have an outcome similar to the luminal A 
subtype) [36].
In summary, despite of methodical criticism, IHC-deter-
mined Ki-67, ER, and PR can be used in clinical routine pri-
marily as a prognostic tool (but not as predictive tool for adju-
vant CT), particularly if there is access to central pathology 
experienced in this field. Moreover, they seem to have an 
 important impact as dynamic markers (e.g. drop of Ki-67 and/
or loss of PR) and indicators for efficacy of ET, as they are 
currently used in the WSG ADAPT [37] and POETIC trials.
Prognostic and Predictive Multigene Signatures
The 21-gene Oncotype DX assay was developed on the 
basis of retrospective analyses across 3 studies of 447 patients 
(all N+ and N0). This analysis was followed by a validation 
study in tamoxifen-treated N0 ER+ patients from the NSABP 
B-14 study [38]. Distant relapse (DR) was observed in 6.8% 
in the low- (L-) and in 30.5% of the high- (H-) risk groups by 
recurrence score (RS). A second validation study in N0 pa-
tients was conducted within the NSABP B-20 collective. 
There was no difference in DR after 10 years in the 
L- (-/+ CT: 96.8/95.6%) and intermediate- (IM-) risk groups 
(-/+ CT: 90.9/89.1%). The H-risk group derived a large benefit 
from adjuvant CT (10 year distant disease-free survival (dis-
tant DFS): 60.5 vs. 88.1%; hazard ratio = 0.26) [39]. 2 analyses 
compared the predictive value of RS and Adjuvant!Online 
with only high RS being a predictive marker for the benefit of 
adjuvant CT in N0 disease [39, 40] – a finding that was also 
previously shown in the context of NACT [41]. The prognos-
tic impact of RS was also confirmed in N+ ET-treated popula-
tions in the TransATAC and SWOG-8814 trials (L vs. H risk: 
17–40% vs. 49–57% DR after 9–10 years). The differences in 
the N+ subgroup were mostly driven by the cohort with 4 pos-
itive lymph nodes, who formed a rather high percentage of 
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is 4% compared with 22–28% in the L- versus the H-risk 
group, respectively. The test identifies only 13–17% of ‘lumi-
nal B’ tumors as L risk, but provides additional prognostic in-
formation to clinical and IHC markers (Ki-67 and ER). It is 
reported to be prognostic for early as well as late recurrences. 
However, there is a distinct biology of early and late recur-
rences with the ER-related gene group (but not the prolifera-
tion group), which is associated with relapses in years 5–10 
[64].
The test is listed by the St. Gallen Consensus [32] because 
of its strong prognostic data, but may not be recommended at 
the moment for the decision on CT in HR+ BC due to the 
 absent predictive data for adjuvant CT. 
Genomic Grade® (GG, bioTheranostics Inc., San Diego, 
CA, USA) is primarily a 97-gene signature in HR+ BC, which 
was published by Sotiriou et al. in 2006 [65]. The aim of the 
original work was to correlate known gene expression data 
with histological grade (HG) 1 and 3 tumors. Most of the 
 differentially expressed genes were shown to be related to 
proliferation. Loi et al. [66] published a validation study, with 
a 10-year DRFS survival in GG1 of 83% in ET-treated N0/N+ 
patients. Later work demonstrated a better prognostic perfor-
mance of GGI compared with Ki-67 IHC, mRNA, and mitotic 
count in a small cohort of N+ CT-treated patients from the 
PACS01 study (5-year DFS GG1 vs. GG3: 89% vs. 64%) [67]. 
Liedtke et al. [68] also reported predictive data for a better 
response to NACT but also worse survival in GG3 versus 
GG1 in HR+ tumors (but not HR– BC).
Two further prospective-retrospective studies were pre-
sented last year. Sotiriou et al. [26] compared the prognostic 
impact of GGI and Ki-67 in the BIG 1–98 monotherapy col-
lective, with 40% of tumors identified as equivocal by GG 
analysis (39% pCR failure rate). In the N0 ET alone cohort, 
99% a 10-year DFS was seen in GG1 compared to 87% in 
GG3 tumors. However, there was a comparable prognostic 
impact of both Ki-67 and GG as continuous variables in this 
cohort. Very similar data from the WSG EC-Doc study have 
also been reported (39% RNA failure rate; 76% GG3). GG 
was prognostic in multivariate analysis (including central 
grade), if used as a continuous, but not if used as a dichoto-
mous, variable. IHC luminal B subtype was a better predictive 
factor for taxane benefit [25].
The Breast Cancer Index® (BCI, bioTheranostics Inc.) 
consists of the HOXB13/IL18BR gene expression ratio, which 
is prognostic [69] and predictive for ET benefit [70], and of 
the molecular grade index (MGI), which is a set of cell cycle- 
related genes. The gene expression ratio predicted outcome in 
untreated and in ET-treated patients better than conventional 
markers. The MGI, as a reflection of the 97-gene GG, was 
shown to provide complementary information to the GG [71]. 
The combination of both markers was validated in the Stock-
holm trial and a continuous BCI was established [72]. DFS at 
10 years was 3% in the Tam-treated group and 50% in the 
untreated group. Interestingly, BCI was powerful in the de-
considered in the decision whether CT is given in ≥ pT1b N0 
and N1mi disease.
Mammaprint® (Agendia NV, Amsterdam, The Nether-
lands) is a 70-gene prognostic signature that was developed in 
2002, and has been recently been complemented by the Blue-
Print® (Agendia NV, for molecular subtype) and TargetPrint® 
(Agendia NV) assays (for ER, PR, HER2). Based on the ex-
pression of 70 genes, patients are allocated to the L- or H-risk 
subgroups, respectively (in both HR+ and HR– BC). A sub-
sequent validation study (including patients from the original 
study) provided a clear correlation between risk assessment 
and relapse risk in 153 N0, mostly CT-naïve, patients (L vs. H 
risk: 13% vs. 56% after 5 years) [52]. A second validation 
study in N0 BC showed a 10-year OS in L- versus H-risk sub-
groups of 88% and 71%, respectively [53]. About 1/3 of pa-
tients were discordant by clinical and genomic assessment, so 
that CT could only be spared effectively in 20%. Later studies 
have shown a strong prognostic impact in N1 BC (n = 241, 
~50% treated by CT; 5-year DFS 98% vs. 80% in L- vs. 
H- risk subgroups) [54], and also in postmenopausal N0 pa-
tients [55]. The 10-year LRR was reported as 5.7% versus 
13.5% in the L- compared with the H-risk subgroups, respec-
tively (n = 1,053) [56]. Knauer et al. [57] performed a meta-
analysis of the predictive impact for adjuvant CT for 7 retro-
spective studies. The analysis showed a hazard ratio of 0.26 
for 5-year DFS in the L-risk subgroup (ET vs. ET + CT: 93% 
vs. 99%, p = 0.2) and a hazard ratio of 0.35 (5-year DFS 76% 
vs. 88%, p < 0.01) in the H-risk subgroup. Meta-analysis data 
of prospective and retrospective studies [58] from the NACT 
setting showed a higher pCR rate (11% vs. 6%) after NACT 
in H- versus L-risk HR+ patients, and a prognostic impact of 
pCR in H-risk disease but a better survival in the L-risk BC 
[59]. The prospective observational RASTER study revealed 
a better 5-year distant-recurrence-free survival (DRFS) in the 
L- compared to the H-risk subgroup (97% vs. 91.7%), which 
was independent of Adjuvant!Online allocation after 
61 months of median follow-up [60].
The prospective randomized MINDACT trial, which di-
rectly compared genomic and clinical assessments, has been 
completed (n = 6,527). Discordance in risk assessment was 
 reported in 32% of all cases, but CT could only be spared in 
11.2% of all cases (per protocol) [61].
The EndoPredict® test (Sividon Diagnostics GmbH, Co-
logne, Germany) is another RNA-based tool for ER+ BC that 
is widely used in German-speaking countries. It can be com-
bined with clinical-pathological factors (tumor size and nodal 
status) into an EPClin score and divides patients into an L- or 
H-risk category even though the score itself is a continuous 
variable. The test was developed in mostly L-risk ER+/HER2– 
patients receiving ET alone (65% N0, 10% G3). Pre-specified 
cut-offs were validated on samples from the ABCSG-6 and 
-8 studies, which included clinically L-risk postmenopausal 
patients (mostly G1/2, N0) treated by ET alone [62, 63]. 
At pre-specified cut-offs of EPclin, the 10-year risk for DR 
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value of a multigene assay is strongly dependent on the num-
ber of patients allocated into the IM-risk group and whether 
further clinical markers are included. Recently, Dowsett et al. 
[34] reported high concordance between L- and H-risk assess-
ments (73% and 67%, respectively) obtained by ROR and 
RS. However, there was only a weak concordance in the IM-
risk group (35%). Again, due to slightly different numbers in 
the IM-risk group, there was high prognostic concordance in 
the H- and L-risk groups, but less so in the IM-risk subgroups. 
ROR added some prognostic information to the RS, but the 
converse was not true.
Prat et al. [79] reported a consistent prognostic impact of 
all signatures (ROR, RS, Mammaprint, SET) as independent 
markers in the multivariate analysis (despite of a very low 
overlap between the individual genes, < 25%), so that a com-
bination of these signatures increased the performance. ROR 
and RS showed the highest concordance. The results of the 
RxPonder trial are needed before final conclusions regarding 
a direct comparison between ROR-Score and RS can be 
drawn. This is a secondary objective of the trial. 
Conclusions
The various genomic signatures presented in this review 
 reflect the heterogeneity of HR+ early BC and its distinct 
prognostic groups in a highly reproducible way. Valid analyti-
cal data are available for most of these signatures (e.g. for 
 Oncotype DX, Mammaprint, EndoPredict, PAM50), and 
show: a high correlation between the same patients samples 
[80]; a high inter-laboratory correlation [53, 81, 82]; and good 
correlations between core biopsies and whole block samples 
[83, 84]. Although a multivariate prognostic effect of such 
genomic tools has been shown in most retrospective studies, it 
should be noted that several analyses did not include impor-
tant prognostic variables such as Ki-67 and/or PR. Despite of 
their controversial reproducibility, inclusion of independently 
and centrally determined IHC factors is definitely required 
before a general recommendation to widely use genomic 
markers can be made. The combination with clinical markers 
seems to increase the prognostic value of these multigene 
tests [8, 40, 62], but may lead to a relative loss of their predic-
tive impact. 
To summarize the decision impact of genomic signatures, it 
is also important to remember that, despite a decision to 
change treatment in 30–40% of cases, absolute sparing of CT 
only occurred in about 10–13% of patients in most retrospec-
tive [85] and prospective [61, 86] studies. Combination of a 
genomic signature (Oncotype DX) with response to short-
term preoperative ET within the WSG ADAPT trial [37] may 
increase this CT-sparing percentage up to 35–40% in patients 
with an originally strong indication for CT.
The IMPAKT 2012 Working Group Consensus Statement 
found the analytical and clinical validity of Oncotype DX and 
tection of both early and late recurrences as the only prognos-
tic factor in the multivariate analysis, most likely due to the 
fact that it combines both ER- and proliferation-related fac-
tors [73]. This finding is of immediate clinical significance 
since, in a nested case-control study, HOXB13/IL18BR iden-
tified patients in the MA-17 trial who benefitted from ex-
tended ET by letrozole (83 recurrences vs. 166 non-recur-
rences) [74]. Identification of late recurrences was also as-
sessed within the TransATAC trial. L-risk patients had a 10-
year DR of 4.2% (compared to 17% of patients in the H-risk 
group with a 30% DR). Although the prognostic impacts of 
BCI, RS, and ROR were similar over the first 5 years, only 
BCI was predictive for late recurrences over the following 
5–10 years.
Last but not least, the sensitivity to the ET index (SET) 
needs to be mentioned here as an example of second genera-
tion signatures. Symanns et al. [75] identified 165 genes co-
regulated with ER. The signature is predictive of ER pathway 
activity and has a prognostic impact in patients receiving ET 
(with/without NACT, n = 523), but not in untreated patients 
(n = 341).
Concordance Between Prognostic Tools
The current St. Gallen Consensus recommends the use of 
multigene signatures particularly in luminal B disease for 
 selection of patients who should undergo adjuvant CT [32]. 
As mentioned previously, there is only weak to moderate con-
cordance between genomic tools and IHC classification of 
HR+ BC. Prat et al. [35] reported k values of 0.2–0.41 for IHC 
versus PAM50 (in the earlier work k = 0.47 [9]), and 35–52% 
of IHC luminal B tumors were re-classified to luminal A using 
PAM50. It is important to state that the PAM50/ROR score 
provided additional prognostic information to that of the IHC 
subtype and IHC4, but the converse was not true. Similar data 
have been reported for the MINDACT trial, where only a 
71% concordance between luminal subtypes by BluePrint and 
IHC (Ki-67 cut-off of 14%) was detected. In this study, 61% 
of ‘IHC-based luminal B subtypes’ were classified as L-risk 
luminal A by BluePrint [76].
The prospective planB study showed a comparable correla-
tion between central grade, Ki-67 and RS (n = 2,566). 11% of 
luminal B (Ki-67 ≥ 20%) tumors were L risk and 48% IM risk 
by RS. The correlation between central grade and RS was 
poorer (k of 0.32) [77]. Only a moderate correlation of 
Rs = 0.65 was found between Oncotype DX and EndoPredict 
(Sividon Diagnostics GmbH, Cologne, Germany) in a small 
study, due mainly to 61% of H-risk patients by EndoPredict 
being classified as L or IM risk by RS [78].
Depending on different patient selection criteria, good 
concordance between H-risk assessments by the different 
genomic signatures seems to exist, but there are slightly diver-
gent results in the L- and IM-risk groups. The prognostic 
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discussed in this manuscript all have the potential to support 
clinical decision making in early BC, and thus to help both 
avoiding overtreatment by adjuvant CT as well as 
undertreatment. 
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